LlewCD

Lead Pharmacist for Myeloid Neoplasms at Guys and St Thomas’ NHS Foundation Trust

[MPN Voice @MPNVoice]

Dear MPN Voice community,
We are inviting people living with Polycythaemia Vera (PV), Essential Thrombocythaemia (ET), or Myelofibrosis (MF) who have received treatment with interferons (Pegasys or BESREMi) to take part in a short, anonymous survey.

This important study aims to gather patient experiences during the recent international interferon shortages. The findings will help inform clinical care and improve access to treatment for people with MPNs both in the UK and internationally.

👉 The survey takes around 10–15 minutes to complete.

Please only complete it once.

Take part now by clicking the hyperlink here or scanning the QR code.

https://t.co/Yp6ua1lPQV

Thank you for helping us improve care for the MPN community worldwide.

#myeloproliferativeneoplasm #bloodcancerawarenessmonth #chronicillness #mpnsm

[Priya Sriskandarajah @PriyaSriRajah]

Today we walked from Guys to St Thomas then back to raise awareness for MPN. Lovely morning and such a great cause for our amazing patients. @MPNVoice @G_ICEMD @harrisoncn1 @WoodleyClaire @nat_curto #mpn

[John Damianos, M.D. @john_damianosMD]

Iron deficiency review

https://t.co/WkLUHhF2ET

[MPN_Hub @MPN_Hub]

CONGRESS #ASH24 | PRESENTATION
John Mascarenhas, @IcahnMountSinai discussed results from the phase III BOREAS study. Navtemadlin treatment improved biomarkers of disease burden in pts with R/R MF, including changes in CD34+ counts, driver mutation burden, and serum inflammatory cytokine levels. The POIESIS study will further investigate navtamadelin in pts with subotimal response to rux. Follow our live feed for more updates: https://t.co/NqDgLO6DlQ
#MPN #MPNsm

[LlewCD @LlewCD]

@RenoHemonc @BrJHaem @jm_osullivan @beth_psaila Pacritinib is currently commercially unavailable in the UK but is commented on in the paper regarding where it may fit in the greater schema

[LlewCD @LlewCD]

A lovely review of JAKi and when to use from @beth_psaila and @jm_osullivan the landscape is moving quickly and this is fantastic summary of clinicians can utilise the options

[British Journal of Haematology @BrJHaem]

In a Nutshell: When, which and how to switch: Navigating JAK inhibitors in myelofibrosis
@jm_osullivan @beth_psaila
https://t.co/LMlFc2Tf2K

[Gonzalo Bentolila @GonzaloBentoli1]

Improving the outcome in MF.
A lot to investigate 🔬 and have real life data, especially in GvHD prophylaxis.
Chair: @DrLornan Hernandez Boluda JC.

[DrDonalMcLornan @DrLornan]

👉🏼👉🏼Wonderful updates from two ⭐ ⭐ members of the CMWP of @TheEBMT : Incorporation of key PRO in clinical trials for mds/mpn @gulderenesra and state of the art CAR T therapy for CALR+MPN @ARampotas ! Congrats both 👏🏻 👏🏻 @uclcancer #MPNsm

[Alex Bick @AlexBickMDPhD]

🩸New research in @BloodJournal led by @beckyzon reveals that JAK2-mutant #CHIP significantly increases the risk of venous thromboembolism (VTE). Proud to make a small contribution to this important work! #VTE @ASH_hematology
https://t.co/No4gAADuNm

[British Journal of Haematology @BrJHaem]

Are we there yet? CAR-T therapy in multiple myeloma
https://t.co/nJwVyAwtXn
@EitanMirvis

[Kiruthikah Thillai @Kiruthikah_T]

Our new podcast for anyone affected by pancreatic cancer is out, the first couple of episodes focus on what to expect from surgery, sign up to hear this and future episodes about chemo, stents , radiotherapy , trials plus more and hear patient stories https://t.co/irvPod318Z

[Blood Journals Portfolio @BloodPortfolio]

JAK2-mutant CHIP confers a greater risk of VTE than heterozygous thrombophilia but is present at a lower frequency in the general population. https://t.co/CURMDRbaZq #thrombosisandhemostasis #hematopoiesisandstemcells

[JAMA @JAMA_current]

Polycythemia vera is a clonal myeloproliferative neoplasm that causes erythrocytosis and is typically associated with a JAK2 gene variant. This narrative review investigates the diagnosis, symptoms, and management of polycythemia vera.

https://t.co/KVMFTHCNRa

[LlewCD @LlewCD]

Really exciting detail about the role of IVIg in BSAb and how the cadence of dosing can influence infections
.
#ASH24

[Muzaffar Qazilbash @Transplant_Doc]

#ASH24 Effects of IVIG on Infections in Recipients of Teclistamab for MM. IVIG within the past 30 days may lower the risk of high-grade and bacterial infections #mmsm #bmtsm @hcheruvalath @MeeraMohanMD https://t.co/TxXf4z3oe4

[LlewCD @LlewCD]

Interesting expansion of immunotherapy to the Myelodysplastic arena.
.
The questions of immunotherapy toxicity become ever more prevalent in healthcare and how we identify and manage them in routine practice

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Our brand new paper 🚨 led by Dr Ian Bouligny & ⁦@garciamanero⁩
A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms | ⁦⁦@LeukemiaJnl⁩ https://t.co/htA9v1Oia6

[VJHemOnc @VJHemOnc]

Have you watched our insightful discussion from #iwHRMM24 on the role of bispecific antibodies in treating high-risk #MultipleMyeloma?🩸

Hear from experts @TomBmt133, @AjaiChari, Niels Van de Donk, & @szusmani:
👉https://t.co/3LbJe3kPUZ👈

#MMSM #Myeloma #ImmunoOnc #HemOnc

[MPN_Hub @MPN_Hub]

📝 A review of MPN risk scoring systems published in Blood provides an optimized algorithm for #MPN prognostication to guide treatment strategies.
More news: https://t.co/rg5N6Fz4LG
#MPNsm #MedNews #MedEd

[Nico Gagelmann @NicoGagelmann]

🎉Finally out🎉

Clinical and Immune Effects of Peri-Transplantation JAK Inhibition for Myelofibrosis @AjHematology

👉using JAK inhibitors until engraftment is safe
👉 improved efficacy signals (excellent engraftment, reduced acute GVHD)

#mpnsm

https://t.co/rSJ6PogiTm

[Kiruthikah Thillai @Kiruthikah_T]

Our podcast is out! latest oncology updates for health care professionals - all you need to know about different topics in 30 mins -for consultants /trainees/AHPs/specialist nurses

#guyscanceracademy @ACPUK @myESMO @ASCO

https://t.co/GK6oX9UZB2

[Priya Sriskandarajah @PriyaSriRajah]

Also be aware of new QR4 which outperforms QRISK3 in assessing risk of cardiovascular disease published by Hippisley-Cox et al this year in Nature Medicine